{"id":"W4411638096","doi":"10.1016/j.euo.2025.04.025","title":"PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Manchester Biomedical Research Centre; Merck Sharp and Dohme; Institute of Cancer Research; Prostate Cancer UK; Cancer Research UK; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Movember Foundation","keywords":"Medicine; Pembrolizumab; Prostate cancer; Open label; Oncology; Internal medicine; Castration; Clinical trial; Immune system; Immunotherapy; Cancer; Immunology; Hormone","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006333555,0.0002234814,0.0004904855,0.0001780219,0.0001549181,0.0000255657,0.0001673172,0.00005085764,0.00001279409],"category_scores_gemma":[0.0003996183,0.0001340271,0.00002037787,0.0004866372,0.0008849293,0.00008491261,0.0001065558,0.0003097175,0.000001759602],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001309445,"about_ca_system_score_gemma":0.001152479,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003531208,"about_ca_topic_score_gemma":0.0001869923,"domain_scores_codex":[0.9973046,0.001238808,0.0004324823,0.0004786713,0.0001773057,0.0003680933],"domain_scores_gemma":[0.9986331,0.0003990078,0.00023873,0.0003141712,0.0002959943,0.0001189881],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7988142,0.02904765,0.07905803,0.0003238519,0.001544949,0.004155347,0.009656498,0.0003488204,0.06513342,0.000943939,0.0001671758,0.01080612],"study_design_scores_gemma":[0.6455635,0.1710769,0.1734029,0.0003878001,0.001527567,0.0001324549,0.001743917,0.0005215253,0.003842903,0.00008884869,0.001232851,0.0004788478],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910343,0.0006409322,0.000007420721,0.0008790258,0.00005149162,0.002337749,0.0000368515,0.00003534964,0.00497683],"genre_scores_gemma":[0.9979701,0.00001270401,0.0007903719,0.0009729522,0.00001518681,0.00007640557,0.00004005967,0.00003557618,0.00008663213],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1532507,"threshold_uncertainty_score":0.5465465,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07294500427301906,"score_gpt":0.3603880609852758,"score_spread":0.2874430567122568,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}